Outcome of patients with peritoneal metastasis from ovarian cancer treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)

• Published in: Pleura and peritoneum Vol. 9; no. 2; pp. 69 - 77
• Main Authors: Foslund, Ingrid Terese, von Magius, Sahra Aisha Vinholt, Ainsworth, Alan Patrick, Detlefsen, Sönke, Fristrup, Claus Wilki, Knudsen, Anja Oer, Mortensen, Michael Bau, Tarpgaard, Line Schmidt, Jochumsen, Kirsten Marie, Graversen, Martin
• Format: Journal Article
• Language: English
• Published: Germany De Gruyter 01-06-2024
• Subjects: Ovarian Cancer; Peritoneal Metastasis; Peritoneal Regression Grading Score (PRGS); Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC); Quality of Life (QoL); Ovarian Cancer; Peritoneal Metastasis; Peritoneal Regression Grading Score (PRGS); Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC); Quality of Life (QoL)
• ISSN: 2364-7671; 2364-768X; 2364-768X
• DOI: 10.1515/pp-2023-0049

There are few data on Pressurized IntraPeritoneal Aerosol Chemotherapy with cisplatin and doxorubicin (PIPAC C/D) in women with primary unresectable or recurrent platinum-resistant peritoneal metastasis (PM) from ovarian cancer (OC). We evaluated survival, histological and cytological response, Quality of Life (QoL) and toxicity after PIPAC C/D in these patients.
Retrospective analysis of patients from the prospective PIPAC-OPC1 and -OPC2 studies. The histological response was evaluated by the Peritoneal Regression Grading Score (PRGS). QoL questionnaires were collected at baseline and after third PIPAC or 60 days. Adverse events were collected until 30 days after the last PIPAC. Demographic and survival data were analysed based on intention to treat. Response, QoL and toxicity were analysed per protocol (≥1 PIPAC).
Twenty-nine patients were included. Five patients (17 %) were non-accessible at PIPAC 1. One patient was excluded due to liver metastases at PIPAC 1. Thus, 23 patients had 76 PIPACs (median 2, range 1-12). Median overall survival was 8.2 months (95 % CI 4.4-10.3) from PIPAC 1. Biopsy data were available for 22 patients, and seven (32 %) patients had a major/complete histological response (PRGS≤2) at PIPAC 3. No cytological conversions were registered. Symptoms and function scores worsened, while emotional scores improved. Three patients had severe adverse reactions (two ileus, one pulmonary embolism); no life-threatening reactions or treatment-related mortality was observed.
PIPAC C/D was feasible and induced histological regression in a substantial proportion of patients with platinum-resistant PM from OC. Larger studies are needed to evaluate impact on survival.